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Interleukin-4 Receptor alpha (IL 4Rα)
Background: Severe IgE-mediated, food-induced anaphylactic reactions are characterized by pulmonary venous vasodilatation and fluid extravasation, which are thought to lead to the life-threatening anaphylactic phenotype. The underlying immunologic and cellular processes involved in driving fluid extravasation and the severe anaphylactic phenotype are not fully elucidated. Objective: We sought to define the interaction and requirement of IL-4 and vascular endothelial (VE) IL-4 receptor a chain (IL-4Ra) signaling in histamine-abelson murine leukemia viral oncogene homology 1 (ABL1)-mediated VE dysfunction and fluid extravasation in the severity of IgE-mediated anaphylactic reactions in mice. Methods: Mice deficient in VE IL-4Ra and models of passive and active oral antigen-and IgE-induced anaphylaxis were used to define the requirements of the VE IL-4Ra and ABL1 pathway in severe anaphylactic reactions. The human VE cell line (EA.hy926 cells) and pharmacologic (imatinib) and genetic (short hairpin RNA knockdown of IL4RA and ABL1) approaches were used to define the requirement of this pathway in VE barrier dysfunction.
Results: IL-4 exacerbation of histamine-induced hypovolemic shock in mice was dependent on VE expression of IL-4Ra. IL-4-and histamine-induced ABL1 activation in human VE cells and VE barrier dysfunction was ABL1-dependent. Development of severe IgE-mediated hypovolemia and shock required VErestricted ABL1 expression. Treatment of mice with a history of food-induced anaphylaxis with the ABL kinase inhibitor imatinib protected the mice from severe IgE-mediated anaphylaxis. Conclusion: IL-4 amplifies IgE-and histamine-induced VE dysfunction, fluid extravasation, and the severity of anaphylaxis through a VE IL-4Ra/ABL1-dependent mechanism. These studies implicate an important contribution by the VE compartment in the severity of anaphylaxis and identify a new pathway for therapeutic intervention of IgE-mediated reactions. Anaphylaxis is a severe, life-threatening allergic reaction that affects both children and adults and male and female subjects in the United States. 1 The most common inciting agents (33.2% of reactions) are foods, particularly peanuts and tree nuts, and food-induced anaphylaxis hospitalization rates for children in the United States have more than doubled from 2000 to 2009. 2 A food-induced anaphylactic reaction encompasses a variety of symptoms that can affect 1 or more target organs, including those of the gastrointestinal, cutaneous, respiratory, and cardiovascular systems. [3] [4] [5] In human subjects compromise of either the cardiovascular or respiratory system defines a severe reaction, 3, 4 and it is postulated that basophil-and mast cell (MC)-derived mediators, through inducing pulmonary venous vasodilatation and fluid extravasation, cause the respiratory and cardiovascular collapse that leads to the severe, life-threatening anaphylactic phenotype. 6 Fluid extravasation in patients with anaphylaxis is thought to be a consequence of capillary fluid leak caused by loss of vascular endothelial (VE) barrier integrity, leading to the movement of fluids, electrolytes, and proteins from the vascular compartment into the interstitial spaces. [7] [8] [9] The VE barrier is maintained by adherens junction (AJ) and tight junction (TJ) proteins. 10 The AJ proteins are the most ubiquitously expressed endothelial cell-cell junctional proteins and act as mechanical anchoring points that permits endothelial TJ protein-protein interactions and interjunctional integrity. 11 The TJ proteins are tethered to the actin cytoskeleton and seal the intercellular space, establishing the dense ''fence'' barrier preventing the bilateral apical-basolateral passage of ions, proteins, and lipids.
11 VE-cadherin is one of the first endothelial cell-specific molecules expressed and is required for endothelial survival, blood vessel assembly, and stabilization. 12, 13 VE-cadherin forms Ca
21
-dependent homophilic interactions with adjacent endothelial cells through actin-linking catenin family proteins and the actin cytoskeleton, establishing the vascular barrier integrity. 11 The stability of the VE-cadherin-catenin-cytoskeleton complex is essential to maintaining endothelial barrier function. 14 Disruption of these processes through receptor-signaling pathways, including nonreceptor kinases, such as Src abelson murine leukemia viral oncogene homology 1 (ABL1), and Arg and myosin light chain kinase, leads to VE-cadherin-mediated AJ disorganization or VE-cadherin internalization and loss of endothelial barrier integrity. [14] [15] [16] [17] [18] [19] [20] The cellular and molecular pathways that directly contribute to the severe anaphylaxis phenotype are unclear. Clinical studies have reported increased levels of IL-4 and histamine in the sera of human patients with severe anaphylaxis. 21 While histamine, but not IL-4 levels were associated with severe disease, 22 there is likely involvement of both of these molecules in expression of the severe disease phenotype. We and others have demonstrated that symptoms of food-induced anaphylaxis in mice are dependent on IgE/MC and histamine type I receptor signaling and that the severity of the reaction positively correlates with an increase in hemoconcentration (an indication for fluid extravasation and hypovolemic shock). [23] [24] [25] [26] In vitro experimental evidence suggests that IL-4 modulates VE barrier properties, [27] [28] [29] and we have demonstrated that IL-4 can interact with vasoactive mediators to increase hemoconcentration and the severity of anaphylaxis. 30, 31 However, the cellular target of these IL-4-mediated effects and the underlying IL-4 receptor a chain (IL-4Ra)-dependent signaling processes involved in the amplification of histamineinduced VE barrier dysfunction and fluid extravasation in IgEmediated reactions are not yet fully understood.
Here we examine the relationship between IL-4 and histamine in IgE-mediated VE leak and hypovolemic shock. We show that IL-4 amplifies histamine-induced hypovolemic shock through VE IL-4Ra chain-dependent process. Furthermore, we show that IL-4 and histamine stimulate ABL1 kinase activity in VE cells and VE barrier dysfunction was inhibited by pharmacologic and genetic ablation of ABL1 activity. Importantly, by using both passive and active models of food-induced anaphylaxis, treating mice with the ABL kinase inhibitor imatinib protected the mice from the severe IgE-mediated anaphylactic phenotype after allergen exposure. These studies implicate an important contribution by the IL-4Ra/ABL1 signaling pathway in the VE compartment in the severity of IgE-and histamine-induced anaphylaxis.
METHODS Animals
Intestinal IL-9 transgenic (iIL9Tg) mice were generated, as previously described. 32 Wild-type (WT) BALB/c mice were originally provided by Charles River laboratories (Wilmington, Mass) and bred in-house at Cincinnati Children's Hospital Medical Center (CCHMC; Cincinnati, fl/fl mice, 35 and iIL-9Tg mice were used to generate mice lacking ABL1 in VE cells. 36 Age-, sex-, and weight-matched littermates were used as control mice in all experiments. Mice were maintained and bred in a clean barrier facility and were handled under an approved Institutional Animal Care and Use Committee protocols at the CCHMC animal facility.
Oral antigen-induced anaphylaxis
Six-to 8-week-old mice were sensitized and challenged, as previously described. 23 In some experiments mice received imatinib mesylate (Santa Cruz Biotechnology, Dallas, Tex) administered intraperitoneally (1.25 or 1.75 mg/ 100 mL distilled water per mouse) 2 hours before ovalbumin (OVA) challenge.
Passive anaphylaxis
Mice were injected intravenously with 20 mg/200 mL of anti-IgE (IgG 2a mAb to mouse IgE; EM-95; obtained from Fred Finkelman, CCHMC).
37 EM95 cross-linking to FcεRI leads to MC and basophil activation and degranulation. 
31,38
Passive oral antigen-induced anaphylaxis Mice were primed and challenged, as previously described. 23 Mice received imatinib mesylate (Santa Cruz Biotechnology) administered intraperitoneally (1.25-1.75 mg/100 mL of distilled water per mouse) 2 hours before OVA-2,4,6-trinitrophenol (TNP) challenge.
Anaphylaxis assessments
Hypothermia (loss of body temperature) and hypovolemia (increase in hemoconcentration) were used as indications of an anaphylactic reaction. Rectal temperature was taken with a rectal probe and a digital thermocouple thermometer (Model BAT-12; Physitemp Instruments, Clifton, NJ). Temperature was taken before the challenge and then every 15 minutes for 30 or 60 minutes. For hemoconcentration assessment, blood was drawn by using retro-orbital bleeding into heparinized capillary tubes and centrifuged for 5 minutes at 10,000 rpm. Hematocrit (percentage of packed RBC volume) values were calculated, as previously described. 31 
MC quantification
The jejunum and ileum were collected and processed for MC quantification by using chloroacetate esterase staining, as described previously. 23 
ELISA measurements
Mouse mast cell protease 1 (mMCPT-1) serum levels were measured by means of ELISA, according to the manufacturer's instructions (eBioscience, San Diego, Calif).
Cell lines and culture
The EA.hy926 cell line (human VE cell line; ATCC, Manassas, Va) was cultured in Dulbecco modified Eagle medium supplemented with 10% FBS (Atlanta Biologicals, Flowery Branch, Ga), nonessential amino acids (0.1 mmol/L), sodium pyruvate (1 mmol/L), HEPES (10 mmol/L), and 13 penicillin and streptomycin (50 mg/mL) in a humidified incubator (5% CO 2 at 378C). 39, 40 All reagents were obtained from Gibco, Life Technologies (Waltham, Mass), unless stated otherwise.
ABL kinase activity assay
Cells (3 3 10 6 /well) were plated in a 6-well plate and grown for 24 hours. Cells were pretreated with IL-4 (10 ng for 24 hours; PeproTech, Rocky Hill, NJ) before imatinib treatment (10-100 mmol/L for 3 hours; Santa Cruz Biotechnology), followed by histamine (10 mmol/L for 30 minutes; SigmaAldrich) stimulation. To assess for ABL1 kinase activity, ABL1 was immunoprecipitated from treated EA.hy926 cells for a subsequent measurement of Homo sapiens v-crk sarcoma virus CT10 oncogene homology -glutathione-S-transferase (CRK-GST) phosphorylation. The ABL1 activation assay was performed, as described by Dudek et al. 41 In vitro permeability EA.hy926 cells were plated on transwells (12-mm dimeter, 0.4-mm pore; Polyester Membrane Insert, Corning, NY), and cells were seeded and cultured until a monolayer formed. Transendothelial resistance (TER) was monitored with an EVOM/Endohm (WPI, Sarasota, Fla), and endothelial monolayers with a TER of greater than 100 V/cm 2 were used for all experiments. Monolayers were mounted between the hemichambers of an Ussing apparatus (P2300 Ussing chamber; Physiologic Instruments, San Diego, Calif), and 0.33 cm 2 of cell monolayer was exposed to 6 mL of Krebs buffer at 378C. The transendothelial potential difference was detected with 2 paired electrodes that contain 4% agar in 3 mol/L KCl. The electrodes were connected to a voltage clamp amplifier (VCC MC8, multichannel voltage/current clamp; Physiologic instruments). Compensation for the electrode potential difference and fluid resistance was done before mounting the monolayer onto the chamber. To establish equilibrium, the potential difference was continuously monitored under open-circuit conditions for 15 minutes. Thereafter, the monolayers were voltage clamped at 0 mV while continuously measuring the short circuit current. Voltage pulses (10-mV square waves sustained for 200 ms) were delivered every 20 seconds to yield a current response for calculating resistance across a mucosa (resistance) by using Ohm's law. IL-4-stimulated (100 ng/mL; 24 hours), histamine-stimulated (100 mmol/L; 30 minutes), and vehicle-stimulated endothelial monolayers were placed in Ussing chambers, in which TER was measured, as described previously. 42 To measure paracellular flux, horseradish peroxidase (HRP) solution was left for 30 minutes at room temperature before the assay. The assay was started by adding 4 mg/mL HRP to the apical side of the monolayers to measure flux from the apical to the basolateral direction. Afterward, aliquots of 250 mL from the basolateral side were collected at 30, 60, 90, 120, 150, and 180 minutes. HRP was assayed colorimetrically (BD OptEIA; BD, San Jose, Calif), according to the manufacturer's instructions.
Lentiviral transduction
Bacterial glycerol stock (Sigma-Aldrich) containing short hairpin RNA (shRNA) plasmid DNA was used to generate lentiviral particles containing target shRNA. In brief, 1 mL was incubated at 378C for 30 minutes in terrific broth without antibiotic and then cultured in Luria broth (LB) agar with ampicillin (100 mg/mL) to expand the bacterial glycerol stock. After an overnight incubation, a single colony was expanded by incubating with 3 mL of LB plus ampicillin for 8 to 10 hours and then moved to 300 mL of LB with ampicillin and incubated overnight. shRNA plasmid DNA was extracted with the Qiagen Plasmid Maxi Kit (Qiagen, Hilden, Germany). Afterward, lentiviral partials were produced by CCHMC's Viral Vector Core.
Cells were transduced with 5 mL of concentrated lentiviral particles or control shRNA lentiviral particles containing an empty vector (PLKO.1). Transduction was carried out with media in the presence of 10 mg/mL polybrene (Sigma-Aldrich). Cells were incubated for 24 hours at 378C, and then the media was replaced with fresh media. Cells were selected with 10 mg/ mL puromycin (Gibco, Grand Island, NY) 2 days after transduction.
Flow cytometry
Mice were injected with IL-4C (1 mg of IL-4 1 5 mg of anti-IL-4 mAb) or vehicle. Twenty-four hours later, mice were killed, and spleens were harvested. The spleen was homogenized and then the suspension was filtered with a 40-mm-pore cell strainer to prepare a single-cell suspension. Afterward, the cell solution was centrifuged (5 minutes at 1200 rpm). RBCs were lysed with RBC lysing buffer (Sigma-Aldrich) and incubated for 2 minutes at 378C; the reaction was stopped with 30 mL of 13 HBSS buffer (Gibco). Cells were centrifuged and resuspended with 200 mL of FACS buffer (0.1% sodium azide, 2% FCS, and 13 PBS) at 2 3 10 6 cells/mL and stained with anti-mouse MHC class II (I-A) fluorescein isothiocyanate and anti-mouse/human CD45R/B220 peridinin-chlorophyll-protein complex/Cy5.5 antibodies (BioLegend, San Diego, Calif). After fixation with 1% paraformaldehyde (30 minutes at 48C), the cells were resuspended in 200 mL of FACS buffer. Flow cytometric data acquisition and analysis were performed on BD LSR Fortessa with FACSDiva software (BD Biosciences, Mountain View, Calif).
Immunofluorescent assay
Antibodies and concentrations used were as follows: anti-IL-4Ra at 1:400 (no. sc-28361; Santa Cruz Biotechnology) and anti-MECA32 at 1:100 (no. NB100-77668; Novus Biologicals, Littleton, Colo). Immunofluorescence was performed, as previously described, 43 except that the antigen retrieval step was performed with a decloaking chamber for 30 seconds at 1258C.
Statistical analysis
Data are expressed as means 6 SDs, unless otherwise stated. In experiments comparing multiple experimental groups, statistical differences between groups were analyzed by using the 1-way/2-way ANOVA parametric test. In experiments comparing 2 experimental groups, statistical differences between groups were determined by using a Student t test. A P value of less than .05 was considered significant. Correlation analysis was performed with the Spearman rank correlation coefficient. All analyses were performed with Prism 7.0 software (GraphPad Software, San Diego, Calif).
RESULTS
IL-4 enhances histamine-induced hypovolemic shock through vascular endothelium-dependent IL4Ra chain signaling
We first examined the effect of IL-4 on histamine-induced increases in hemoconcentration and hypothermia (as an indication for anaphylactic shock severity). WT mice were injected intravenously with IL-4C (a long-acting formula IL-4 complexed with anti-IL-4 39 ) or vehicle and 24 hours later received an intravenous challenge of histamine. Treatment of mice with IL-4C alone did not affect hemoconcentration or body temperature (Fig 1) . In contrast, histamine alone induced an increase in hemoconcentration that was associated with hypothermia (Fig 1) . Notably, this response was potentiated by pretreatment with IL-4C, suggesting that IL-4 amplifies histamine-induced hypovolemic shock (Fig 1) .
To determine whether IL-4 amplification of the histamine response occurred through direct modulation of VE barrier function, we examined the effect of histamine and IL-4 on the human VE cell line EA.hy926. 39, 40 We show that TER decreased and flux of HRP (40 kDa) increased in histamine-stimulated compared with unstimulated EA.Hy926 cells (Fig 2, A and B) . Importantly, the histamine-induced increase in endothelial cell permeability was enhanced by pretreatment with IL-4 (Fig 2, A  and B) . Collectively, these data suggest that IL-4 amplifies histamine-induced VE permeability through direct activation of VE cells.
To identify the requirement of IL-4 signaling on VE cells in the exacerbation of histamine-induced hypovolemic shock in vivo, we took a transgenic approach using the VE-specific promoter of the junction protein cadherin-5 (also called VE-cadherin). 34 
Cadherin-5
Cre IL-4Ra fl/fl mice (referred to as VE DIL-4Ra ) lack expression of the IL-4Ra chain on the VE compartment, whereas cadherin-5
WT IL-4Ra fl/fl mice (referred to as VE IL-4Ra WT mice) were used as a WT control (see Fig E1 in this article's Online Repository at www.jacionline.org). Mice received an intravenous injection of either vehicle or IL-4C and 24 hours later received an intravenous injection of histamine; evidence of hypovolemic shock and hypothermia was evaluated (Fig 3, A) . Intravenous administration of histamine induced hypothermia and increased hemoconcentration in both VE IL-4Ra WT and VE DIL-4Ra mice (Fig 3, B and C) . Pretreating VE IL-4Ra WT mice with IL-4C enhanced histamine-induced hypothermia and hemoconcentration (Fig 3, B and C) . However, IL-4C amplification of the histamine-induced hypovolemic shock was ablated in VE mice (Fig 3, B and C) . Consistent with previous studies, we found that IL-4C alone had no effect on body temperature or hemoconcentration (Fig 3, B and C) . 31 To confirm IL-4C activity in VE DIL-4Ra mice, we evaluated the expression of MHC class II on B cells (B220 DIL-4Ra mice (see Fig E2) . Collectively, these studies indicate that IL-4 amplification of histamine-induced hypovolemic shock was dependent on IL-4 signaling on the VE compartment.
Interestingly, clinical and experimental studies indicate that gain-of-function mutations in IL-4Ra have been associated with increased susceptibility to atopic disease and enhanced allergic inflammatory responses. [44] [45] [46] [47] [48] [49] Given the observation that IL-4/IL4Ra signaling plays an important role in histamine-induced hypovolemic shock, we hypothesized that mice with a gain of function in IL-4 receptor signaling would have increased severity of histamine-induced hypovolemic shock. To test this, we used IL4Ra Y709F mice, 33 which have an activating variant IL-4Ra chain (Fig 3, D-F) . Histamine challenge of IL-4Ra Y709F mice induced a hypovolemic shock response equivalent to that observed in WT mice (Fig 3, E and F) . IL-4C treatment amplified histamineinduced hypothermia and hypovolemic shock in both IL4Ra Y709F and WT BALB/c mice (Fig 3, E and F) . Notably, we observed a significantly greater IL-4C-induced amplification of the histamine-induced hypothermic response in the IL-4Ra Y709F mice than in the BALB/c mice, and this increased hypothermic response was associated with increased hemoconcentration (Fig 3, E and F) . These data indicate that enhanced IL-4Ra signaling can exacerbate histamine-and IL-4-induced hypovolemic shock.
VE IL-4Ra chain deletion attenuated hypovolemic shock induced by passive oral antigen-induced anaphylaxis
To confirm the requirement of IL-4Ra chain expression on VE in IgE/MC-mediated anaphylaxis, we used a passive oral antigentriggered IgE-mediated anaphylaxis model. 23 Cadherin-5 Cre IL4Ra fl/fl mice were backcrossed on the iIL-9Tg background (referred to as iIL-9Tg VE DIL-4Ra mice). iIL-9Tg VE DIL-4Ra and iIL-9Tg VE IL-4Ra WT mice were injected with anti-TNP IgE with IL-4C and then administered TNP-OVA 24 hours later (Fig 4, A) . Oral gavage of TNP-OVA increased hemoconcentration and induced shock in both iIL-9Tg VE IL-4Ra WT and iIL-9Tg VE
DIL-4Ra
mice treated with anti-TNP IgE (Fig 4, B and C) . Notably, pretreatment of the iIL-9Tg VE IL-4Ra WT mice with IL-4C exacerbated hypothermia and hemoconcentration; however, the IL-4 enhancement was absent in iIL-9Tg VE DIL-4Ra mice (Fig 4, B  and C) . The reduced disease in iIL-9Tg VE DIL-4Ra mice could not be explained by decreased MC activation or levels or immunoglobulin levels because serum mMCPT-1, intestinal MC, and immunoglobulin (IgE and IgG 1 ) levels were comparable between groups (Fig 4, D, Histamine and IL-4 modulation of paracellular leakage in the human VE cell line (EA.hy926) is ABL1 kinase dependent Next, we were interested in defining the signaling pathways involved in IL-4C amplification of histamine-induced VE dysfunction. Recent studies have identified roles for members of the ABL family of nonreceptor tyrosine kinases (ABL1 and Arg) and RhoA and Rho-associated protein kinase in histamineinduced VE leakage; therefore we examined histamine and IL-4C induction of ABL1 kinase activity. 15, 50 Using the immortalized human endothelial cell line (EA.hy926), we first examined ABL1 kinase activity after histamine and IL-4C stimulation. We found that histamine or IL-4C alone stimulated ABL1 kinase activity, as indicated by GST-CRK (a known ABL1 substrate) phosphorylation (Fig 5, A) . Notably, EA.hy926 cell costimulation with both histamine and IL-4C amplified ABL1 kinase activity (Fig 5, A) .
To determine the requirement of ABL1 kinase in histamine/ IL-4C-induced barrier function, we used a pharmacologic (imatinib) and genetic (shRNA ABL1 kinase knockdown) approaches. Histamine stimulation of EA.hy926 cells reduced the TER in a dose-dependent manner (see Fig E4, A, in this article's Online Repository at www.jacionline.org). Pretreatment of EA.hy926 cells with imatinib antagonized histamineinduced reduction in TER and paracellular HRP-flux (see Fig  E4, B and C, in this article's Online Repository at www. jacionline.org). Pretreatment of EA.hy926 cells with imatinib blocked IL-4 amplification of histamine-induced VE barrier dysfunction in a dose-dependent manner (Fig 5, C and D) . Notably, the decreased VE response in the presence of imatinib was associated with decrease of ABL1 kinase activity (Fig 5, B) . Consistent with these observations, pretreating shRNA ABL1-transduced EA.hy926 cells with histamine or histamine and IL-4 did not induce VE barrier dysfunction (Fig 5, F and G) . EA.hy926 monolayers were pretreated with vehicle or IL-4 (100 ng/mL) for 24 hours and stimulated with histamine (100 mmol/L for 30 minutes) or vehicle, and TER and HRP flux were measured, as described in the Methods section. Data are represented as means 6 SDs (n 5 3 wells per group from n 5 2 independent experiments. **P < .01, ***P < .0001, and ****P < .0001. ns, P > .05. (A and D) , maximum temperature change (B and E), and hematocrit percentage (C and F) in iIL-9Tg VE DIL-4Ra and iIL-9Tg VE IL-4Ra WT mice (Fig 3, A-C) and IL-4Ra Y709F and IL4Ra WT mice (Fig 3, D-F) after intravenous (i.v.) injection with vehicle or IL-4C and intravenous challenge with histamine (0.4 mg). Data are represented as means 6 SDs (n 5 3-10 mice [Fig 3, B] , n 5 3-6 mice [ Fig 3, C] , and n 5 9-13 mice [Fig 3, E and F] per group from n 5 3-4 independent experiments). *P < .05, **P < .01, and ****P < .0001. ns, P > .05.
Taken together, these findings suggest that histamine-induced, IL-4-enhanced paracellular leakage is dependent on the VE ABL kinase ABL1 kinase.
VE ABL1 kinase involvement in passive anaphylaxis in iIL-9Tg VE DABL1 mice
We next examined the requirement of the VE ABL1 kinase in passive anaphylaxis by using mice lacking ABL1 expression in the VE compartment. Tie2
Cre transgenic mice have been used as a genetic tool for analyses of endothelial cell-specific gene targeting. 36 Therefore we used Tie2 Cre ABL1 fl/fl mice on an iIL9Tg background (referred to as iIL-9Tg VE DABL1 mice) and WT control iIL9Tg Tie2
WT ABL1 fl/fl mice (referred to as iIL-9Tg VE ABL1 WT mice). iIL-9Tg VE DABL1 mice and iIL-9Tg VE ABL1WT mice received an intraperitoneal injection with vehicle or imatinib 30 minutes before intravenous injection with anti-IgE mAb (EM95; see Fig E5, A, in this article's Online Repository at www.jacionline.org). In iIL-9Tg VE ABL1WT mice intravenous anti-IgE mAb induced hypothermia and increased hemoconcentration, with these changes being sensitive to imatinib inhibition (see Fig E5, B and C) . Importantly, iIL-9Tg VE DABL1 mice showed attenuated hypothermia comparable with that observed in iIL-9Tg VE ABL1WT mice treated with imatinib (see Fig E5,  B) . Importantly, levels of MC activation and degranulation were similar between groups (see Fig E5, D) . Collectively, these data indicate a requirement for VE ABL1 in hypovolemic shock induced by IgE.
ABL kinase inhibitor attenuated passive oral antigen-induced anaphylaxis
To determine whether ABL kinase inhibitors could suppress the development of symptoms of oral antigen-induced IgE/MCmediated reactions in mice, we examined the effect of imatinib in a passive oral antigen-triggered, IgE-mediated anaphylaxis model. 23 Evidence of anaphylaxis was evaluated in iIL-9Tg mice receiving an intravenous injection of anti-TNP IgE, 24 hours later receiving either vehicle or imatinib (16-70 mg/kg per mouse; 2 hour), and subsequently undergoing oral gavage with TNP-OVA (Fig 6, A) . In vehicle-treated mice oral challenge of TNP-OVA induced shock, which was associated with an increase in hemoconcentration (Fig 6, B and C) . Pretreating mice with imatinib before TNP-OVA administration protected the mice from hypothermia and hemoconcentration (Fig 6, B and C) . Importantly, imatinib-mediated protection was not associated with reduced MC degranulation because mMCPT-1 levels were comparable between all groups (Fig 6, D) .
Imatinib is known to target c-KIT, which is required for optimal MC degranulation. 51, 52 Although mMCPT-1 levels were not significantly different between groups, mMCPT-1 levels in imatinib-treated mice were lower than those in vehicle-treated mice (Fig 6, D) . To confirm that the imatinib-mediated protective effects were not due to decreased MC degranulation, we examined the relationship between mMCPT-1 levels and onset of the hypothermic response (Fig 6, E) . We show that 10 of 11 mice in the vehicle-treated, TNP-OVA-challenged group with mMCPT-1 levels of greater than 10,000 ng/mL were hypothermic (> _1.58C temperature loss) and that no mice (0/6) with less than 10,000 ng/mL mMCPT-1 had hypothermia (Fig 6, E and F) . Therefore if we set a cutoff threshold of 10,000 ng/mL mMCPT-1 or greater as a level of MC degranulation sufficient to induce symptoms of anaphylaxis, this provides us with 90% or greater confidence that mice with 10,000 ng/mL mMCPT-1 or greater will develop evidence of anaphylaxis. Examining mMCPT-1 levels from the imatinib-treated, TNP-OVA-challenged group revealed that 10 of 13 mice had 10,000 ng/mL mMCPT-1 or greater and were protected from hypothermic response (> _1.58C temperature loss; Fig 6, E and F) . Therefore the protection from hypothermia in those mice is unlikely due to an effect on MC degranulation.
mMCPT-1 is a surrogate for MC degranulation, and the hypothermic response is histamine dependent; therefore we examined histamine levels after TNP-OVA administration in anti-TNP IgE-primed mice treated with vehicle or imatinib. TNP-OVA administration induced a significant increase in histamine levels in the vehicle-treated group, which was comparable with histamine levels in the imatinib-treated group (Fig 6, G) . These DIL-4Ra and iIL-9Tg VE IL-4Ra WT mice injected intravenously (i.v.) with IL-4C mixed with anti-TNP IgE and then orally gavaged (o.g.) the next day with TNP-OVA. Data are represented as means 6 SDs (n 5 3-13 mice per group from n 5 4 independent experiments). *P < .05, **P < .01, ***P < .0001, and ****P < .0001. ns, P > .05. studies suggest that imatinib protection occurs mainly through inhibition of ABL kinase activity independent of MC degranulation. Collectively, these data indicate that imatinib can reduce the severity of IgE/MC-driven anaphylaxis and that this effect is independent of MC degranulation.
ABL kinase inhibitor attenuated pre-existing oral antigen-induced anaphylaxis
Next, we examined the ability of the ABL kinase pharmacological antagonist imatinib to attenuate an established food allergy reaction in mice. 23 BALB/c WT mice were primed (Fig 5, A) and in the presence of imatinib (Fig 5, B) . C, D, F, and G, TER (Fig 5, C and F) and HRP flux (Fig 5, D and G) of EA.hy926 cells and EA.hy926 cells transduced with ABL1 shRNA or empty vector (PLKO-1) pretreated with IL-4 (10 ng/mL) and stimulated with histamine in the presence and absence of imatinib (100 mmol/L). E, ABL1 levels in EA.hy926 cells transduced with ABL1 shRNA lentiviral particles or an empty vector (PLKO-1) detected by using Western blotting. In Fig 5, C, D , F, and G, data are represented as means 6 SDs (n 5 3 wells per group from 2 representative experiments). *P < .05, ***P < .0001, and ****P < .0001. ns, P > .05.
intraperitoneally with OVA-alum and subsequently challenged by means of repeated oral gavage with OVA (Fig 7, A) . By the sixth allergen challenge, mice experienced symptoms of food inducedanaphylaxis, including hypothermia and diarrhea. 23, 32, 53 Before the seventh challenge, mice were stratified into 2 groups, with some receiving vehicle and others pretreated with imatinib (50-75 mg/kg administered intraperitoneally; 2 hours), and then the mice were challenged with OVA (Fig 7, A) . Oral antigen challenge induced hypothermia in vehicle-treated mice (Fig 7, B  and C) . In contrast, pretreating mice with imatinib protected the (Fig 6, A) , maximum temperature change (Fig  6, B) , hematocrit percentage (Fig 6, C) , and serum mMCPT-1 level (Fig 6, D) in iIL-9Tg mice injected intravenously (i.v.) with anti-TNP IgE (20 mg) and undergoing oral gavage (o.g.) with TNP-OVA. i.p., Intraperitoneal. E and F, mMCPT-1 values versus temperature change after oral challenge (Fig 6, E) and Fisher exact test analysis (Fig 6, F) . G, Serum histamine levels in iIL-9Tg mice after anti-TNP IgE and oral gavage (o.g.) with TNP-OVA in the presence and absence of imatinib. ND, Not detectable. Data are represented as means 6 SDs (n 5 3-9 mice per group [ Fig 6, B-D ] from n 5 3 experiments and n 5 5-6 mice per group [ Fig 6, G] ). *P < .05, **P < .01, ***P < .0001, and ****P < .0001. ns, P > .05. mice from anaphylactic shock; the level of hypothermia and diarrhea were significantly reduced in the imatinib-treated mice compared with the vehicle-treated mice (Fig 7, B-D) . Notably, protection from hypothermia was associated with reduced hemoconcentration (Fig 7, E) in the presence of comparable MC degranulation (mMCPT-1 levels; Fig 7, F) , suggesting that imatinib attenuates histamine-induced fluid extravasation. Collectively, these studies indicate that pretreating mice with imatinib can protect against the development of a severe food-induced reaction in mice with a previous history of severe reactions.
DISCUSSION
Clinical studies suggest a relationship between increased IL-4 and histamine levels and the severity of anaphylaxis. 21, 22, 54 This was supported by animal-based studies indicating that IL-4 can exacerbate IgE-mediated reactions. 31 IL-4 alone has been shown to induce VE barrier dysfunction in vitro. 27, 28 However, the cellular target of IL-4 action and the underlying IL-4Ra-dependent signaling processes involved in amplification of the IgE/MC-histamine-driven VE barrier dysfunction and fluid extravasation was not previously fully understood.
Here we show that (1) IL-4 increased histamine-induced fluid extravasation, and this increase positively correlated with anaphylaxis severity (hypovolemic shock); (2) IL-4 enhancement of histamine-and IgE/MC-induced systemic anaphylaxis symptoms was dependent on signaling through the VE IL-4Ra chain; (3) IL-4 enhanced histamine-induced ABL1 activity and VE barrier dysfunction in human VE cells, which could be antagonized by ABL kinase inhibition; and (4) pharmacologic inhibition of ABL kinases by imatinib protected mice from passive and established oral antigen-induced anaphylaxis through suppression of VE barrier dysfunction and fluid extravasation.
Clinical evidence supports possible involvement of hypovolemia and distributive and cardiogenic shock in the setting of human anaphylaxis 7 ; however, mounting evidence identifies In Fig 7, D, the ratio indicates the number of mice with diarrhea/total number of mice. *P < .05, **P < .01, and ****P < .0001. ns, P > .05.
hypovolemic shock as an important contributor to the cardiovascular collapse that leads to the severe, life-threatening anaphylactic phenotype. [55] [56] [57] Consistent with these observations, aggressive fluid resuscitation has been shown to be an effective treatment for anaphylaxis occurring after achievement of anesthesia. 8, 56 Similarly, anaphylaxis in mice causes fluid extravasation, leading to severe hypovolemia and fatal tissue hypoxia. 58, 59 IgE-mediated MC activation promotes secretion of vasoactive amines (histamine and serotonin) and lipid mediators (leukotrienes and prostaglandins) that are thought to induce VE dysfunction and hypovolemic shock. 60, 61 Consistent with this observation, histamine treatment of mice increases hemoconcentration and hypovolemia-induced shock, 31 and conversely, treating mice with H1R antagonists with or without concurrent H2R blockade attenuates IgE/MC-mediated hypovolemic shock. 25, 62 Here we demonstrate that IL-4 can amplify the IgE-mediated, histamine-induced fluid extravasation through priming of the VE compartment. Previous studies have revealed an important role for IL-4 and IL-4Ra signaling in IgE-mediated anaphylaxis; however, this was thought predominantly to be through its effect on the hematopoietic compartment driving IgE-isotype switch and the associated CD4
1 T H 2 and MC response. 31, [63] [64] [65] We show that IL-4 also acts on the nonhematopoietic compartment, namely the VE compartment, to increase the sensitivity of the VE compartment to histamine. This is supported by our observation that levels of mMCPT-1 were comparable between iIL-9Tg VE DIL-4Ra and iIL-9Tg VE IL-4Ra WT mice, even though the iIL-9Tg VE IL-4Ra WT mice experienced greater hypovolemic shock. Notably, mice lacking expression of IL-4Ra on their VE compartment had histamine-induced anaphylactic shock; however, they were protected from the IL-4-induced amplification of anaphylaxis symptoms, suggesting that VE IL-4Ra chain signaling is not required for histamine-induced hypovolemia but exacerbates the histamine-dependent component.
IL-4 can signal through either the type I (IL-4Ra and gc) or type II (IL-4Ra and IL-13Ra1) IL-4 receptor pathways. The previous demonstration of IL-4-enhanced anaphylaxis in recombinationactivating gene 2/gc-deficient mice (which lack B cells, T cells, MCs, eosinophils, and natural killer cells) indicates involvement of the IL-4 type II receptor and not the IL-4 type I receptor. 31 Interestingly, mutations in the IL4RA gene have been associated with susceptibility to atopic disease. [44] [45] [46] [47] [48] [49] Importantly, gain-of-function mutations in the IL-4Ra chain (E375A, S478P, or Q551R) have been linked to enhanced allergic inflammatory responses, including increased MC counts and IgE levels. [44] [45] [46] [47] [48] [49] Consistent with these observations, murine-based studies have revealed that mutations in IL-4Ra that promote gain of function (IL-4Ra   Y709F   ,  IL-4Ra   Q576R , and IL-4Ra Y500F ) led to enhanced allergic inflammatory phenotypes, including asthma, IgE-mediated responses, and food allergy. 33, [66] [67] [68] [69] We show that pretreating IL-4Ra Y709F mice with IL-4 enhanced histamine-induced hypovolemic shock, suggesting that gain-of-function mutations can increase the severity of food-induced anaphylaxis.
Relevant to this study, Burton et al 63 and Mathias et al 67 demonstrated that IL-4Ra Y709F mice have an enhanced sensitivity to food allergens and that the enhanced IgE/MC-mediated systemic anaphylaxis in IL-4Ra Y709F mice is due to a direct effect on MCs. Of note, Burton et al 63 showed that IL-4Ra Y709F mice had a similar responsiveness to histamine to that of WT mice, suggesting no role for gain-of-function mutations in the IL-4Ra chain in the severity of anaphylaxis. However, these studies were performed in the absence of IL-4 treatment. We show enhanced histamine-induced anaphylaxis with exogenous IL-4 treatment in IL-4Ra Y709F mice, suggesting that gain-offunction mutations in IL-4Ra signaling can affect not only hematopoietic cell function but also nonhematopoietic cell function and severity of IgE-mediated reactions.
Previously, we have demonstrated that the onset of a severe food-induced anaphylaxis in mice requires increased type 2 cytokine levels, food-specific IgE levels, and intestinal mastocytosis. 23 Antigen sensitization and repeated food antigen challenge of sensitized mice promotes an intestinal antigenspecific CD4
1 T H 2 cell/type 2 innate lymphoid cell response, which is thought to drive IL-9 producing mucosal MCs and lead to intestinal mastocytosis. 70, 71 We speculate that the repeated antigen challenge promotes heightened IL-4 levels, leading to increased sensitivity of the VE compartment to MC-derived mediators. The cellular source of IL-4 during these allergic conditions is likely to be CD4
1 T cells and basophils. 72, 73 Repeated oral antigen exposure has been shown to drive antigen-specific CD4 1 type 2 responses and generation of IL-4-dependent, antigen-specific IgE and mastocytosis. 70, 71, 74 Oral antigen exposure will also promote IgE-FcεRI ligation on basophils and MCs and given that IgE-mediated IL-4 responses dependent on FcεRI and can occur independently of MCs but not basophils, suggest that basophils are another likely source of IL-4. 72, 73, 75 Studies of mediators in human anaphylaxis revealed that in patients with anaphylaxis, histamine levels peaked during emergency department arrival and that histamine levels correlated with reaction severity. 22 From our observations, one would predict that IL-4 levels should also correlate with reaction severity; however, IL-4 has been reported to not correlate previously with reaction severity. Interestingly, the most sensitive known in vivo effect of IL-4 is upregulation of B-cell MHC class II expression, 38, 76 and IL-4 doses barely capable of inducing an increase in B-cell class II MHC expression have been shown to be sufficient to enhance anaphylaxis. 31 These data suggest that incremental changes in IL-4 might be sufficient to enhance histamine-induced VE dysfunction and anaphylaxis severity and might explain the lack of association between IL-4 levels and severity of anaphylaxis in human subjects. 22 The mechanism by which IL-4 modulates histamine responses is not fully elucidated. We show that IL-4 amplifies histamine-induced ABL1 kinase activation and that blockade of ABL1 kinase genetically or pharmacologically abrogated histamine-induced VE dysfunction and leak, suggesting that IL-4 modulation of histamine-induced responses is likely through increased ABL1 activity. The ABL family of nonreceptor tyrosine kinases, including both ABL1 and Arg, have been implicated in regulation of endothelial barrier function. 6 Notably, Chislock and Pendergast 15 demonstrated a requirement for activation of the ABL kinases in endothelial permeability induced by thrombin and vascular endothelial growth factor in human microvascular endothelial cells.
VE-cadherin is a critical requirement for assembly and stability of the VE-cadherin-catenin-cytoskeleton complex and maintenance of endothelial barrier function. 12, 13, 77 Histamine is thought to destabilize the VE-cadherin-catenin complex through activating protein kinase C and Rho-associated protein kinase and subsequent downstream activation of myosin light chain, resulting in reduced endothelial cell adhesiveness and increased paracellular permeability. 78 Pharmacologic and genetic blockade of ABL1 has been shown to reduce myosin light chain kinase phosphorylation and VE barrier dysfunction after vascular endothelial growth factor and thrombin stimulation. 15 Collectively, our data suggest that blockade of ABL1 kinasedependent processes does not ablate anaphylaxis but rather dramatically reduces the severity of the IgE-mediated reaction. On the basis of these observations, we suggest that inhibiting ABL1 kinase-dependent processes might be a therapeutic target for diminishing or preventing severe IgE-mediated anaphylactic reactions and could be used in conjunction with desensitization protocols, such as sublingual immunotherapy and oral immunotherapy, to minimize the risk of possible severe adverse reactions. Recently, there has been significant development of second-and third-generation tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML), including secondgeneration TKIs (dasatinib, nilotinib, and bosutinib) and thirdgeneration TKIs (ponatinib, GNF-2, GNF-5, and GNF-7), which act as ATP-binding site competitive inhibitors, and allosteric ABL inhibitors that have distinct efficacy, specificity, and longterm safety. 79, 80 Given that TKIs, such as imatinib, bind and inhibit c-KIT-dependent tyrosine kinase signaling, which is essential for MC development and maturation, an added advantage of these classes of inhibitors is that they can target both MC levels and the VE compartment to attenuate IgE/MC-mediated reactions. [81] [82] [83] Consistent with this argument, long-term treatment with imatinib caused a profound MC deficiency in mice and patients with Philadelphia chromosome positive inversion (PH 1 ) CMLs. 84 Furthermore, a recent study examined the clinical use of imatinib for treatment of patients with severe refractory asthma and demonstrated that imatinib had excellent efficacy, reducing MC counts and activation and asthma symptoms. 85 In conclusion, we show that IL-4 enhances histamine responses through the VE IL-4Ra chain by modulating VE function and amplifying vascular leakage and anaphylaxis phenotypes. We demonstrated that IgE-mediated fluid extravasation and hypovolemic shock in mice are mediated by a histamine-induced, VE ABL kinase-dependent mechanism, possibly through ABL1 kinase. These studies identify that targeting of the ABL1-sensitive VE compartment might be a new pathway for therapeutic intervention and prevention of food-induced severe and life-threatening anaphylaxis and that repurposing TKI inhibitors, such as imatinib, might prevent food-induced reactions.
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Key messages
d IL-4 amplifies IgE-and histamine-induced hypovolemic shock.
d IL-4 amplification of the shock response is dependent on VE expression of ABL1 and IL-4Ra. ) were mounted in Ussing chambers and stimulated with different doses of histamine (0.1-10 mmol/L) for 30 minutes, and TER was determined by using Ohms law. B and C, EA.hy296 cells were pretreated with a different dose of imatinib (0-100 mmol/L) for 3 hours, mounted in Ussing chambers and treated with histamine (100 mmol/L for 30 minutes), and TER (Fig E4, B) and HRP flux (Fig E4, C) were determined. Data are represented as means 6 SDs (n 5 3 wells per group). *P < .05, **P < .01, ***P < .0001, and ****P < .0001. ns, P > .05. (n 5 4-6 mice per group from n 5 3 experiments). *P < .05. ns, P > .05.
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